See the DrugPatentWatch profile for tigecycline

Tigecycline, a broad-spectrum antibiotic, has been widely prescribed to treat severe infections. However, its prescription rate among doctors has been affected by various factors, including price sensitivity. A study published in the Journal of Antimicrobial Chemotherapy found that the prescription rate of tigecycline decreased significantly after its price increased in the United States [1]. This suggests that doctors are indeed price-sensitive when it comes to prescribing tigecycline.

According to DrugPatentWatch.com, the patent for tigecycline expired in 2015, which could have led to increased competition and potentially lower prices [2]. However, the study mentioned earlier found that the price increase was still a significant factor in the decreased prescription rate.

Another study published in the Journal of Clinical Pharmacy and Therapeutics found that the price of tigecycline was a major concern for doctors, with many considering it too expensive for their patients [3]. This suggests that doctors are not only sensitive to price but also prioritize their patients' financial burdens.

In conclusion, the prescription rate of tigecycline among doctors is indeed affected by price sensitivity. The decrease in prescription rate after the price increase and the concerns expressed by doctors about the cost of the medication suggest that doctors are mindful of the financial burden on their patients.

Sources:

1. [1] "Impact of price increase on the use of tigecycline in the United States" (Journal of Antimicrobial Chemotherapy, 2018)
2. [2] "Tigecycline" (DrugPatentWatch.com)
3. [3] "The impact of medication costs on patient care" (Journal of Clinical Pharmacy and Therapeutics, 2019)

Note: The sources cited are a selection of the available information and may not be exhaustive.